Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose Escalation, Open-label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacodynamics, and Pharmacokinetics of EA5 Injection in Adult Participants With Antiphospholipid Syndrome (APS) and Recurrent Thrombosis Under Standard-of-Care Background Therapy

NCT07632976 is registered in ClinicalTrials.gov with Shanghai Lanyi Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07632976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07632976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose Escalation, Open-label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacodynamics, and Pharmacokinetics of EA5 Injection in Adult Participants With Antiphospholipid Syndrome (APS) and Recurrent Thrombosis Under Standard-of-Care Background Therapy
Lead sponsor
Shanghai Lanyi Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 25, 2026
Completion date
December 31, 2027
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid syndrome (aps), thrombosis